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Abstract 
Introduction 
Breast cancer arises from the tissues of the breast and most commonly origi-
nates in the cells that line the ducts due to dysregulation of the cell cycle. 
Abemaciclib has been approved by the US Food and Drug Administration 
(FDA) in September 2017 for the following two indications: abemaciclib as 
monotherapy for patients with hormone receptor (HR)-positive, human epi-
dermal growth factor 2 (HER2)-negative advanced breast cancer (ABC) who 
have received prior endocrine therapy (ET) and chemotherapy for metastat-
ic disease, and abemaciclib in combination with fulvestrant in women with 
HR-positive, HER2-negative ABC who had disease progression following 
ET. Currently, abemaciclib is not approved in Europe. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer (overall: 141 references). Quality assessment 
was conducted to assess the risk of bias at the study level based on the EU-
netHTA internal validity for randomized controlled trials. Furthermore, the 
magnitude of clinically meaningful benefit that can be expected from 
abemaciclib was evaluated based on, both the original and an adapted ver-
sion of, the Magnitude of Clinical Benefit Scale (MCBS) developed by the 
European Society for Medical Oncology (ESMO). 
Results of the MONARCH 2 trial 
Between 7 August 2014 and 29 December 2015, 669 patients were randomly 
assigned to receive either abemaciclib plus fulvestrant (n = 446) or placebo 
plus fulvestrant (n = 223). At the median follow-up of 19.5 months, the 
primary endpoint progression-free survival (PFS) showed a statistically 
significant increase of 7.1 months (median) in the intention-to-treat (ITT) 
population of the abemaciclib arm. In addition, the improvement of the 
overall response rate (ORR) in the ITT population of the abemaciclib arm 
(+19.1%) was statistically significant. However, at the time of data cut-off 
(February 2017), overall survival (OS) results were not mature as well as 
quality of life (QoL) outcomes are not reported. The most frequent adverse 
events (AEs) of any grade were diarrhoea, neutropenia, nausea, fatigue, and 
abdominal pain. Grade ≥3 AEs could be observed more commonly in the 
abemaciclib group (60.5%) than in the placebo group (22.8%). In addition, 
discontinuation rates (15.9% vs. 1.3%) as well as dose reductions (42.9 vs. 
1.3) due to AEs occurred more commonly in the abemaciclib group.  
Conclusion 
In conclusion, the treatment with abemaciclib offers a statistically signifi-
cant improvement in PFS of 7.1 months and ORR (+19.1%) with an inferior 
safety profile at high costs. Due to the immature OS data and the missing 
QoL results there is a need of long-term data to avoid a systematic overesti-
mation of the treatment effect of abemaciclib. In the future, the identifica-
tion of a robust predictive biomarker to identify the most suitable patients 
will be crucial for the class of CDK4/6 inhibitors. Finally, direct compari-
sons of abemaciclib to palbociclib and ribociclib are essential to investigate 
which treatment option is most beneficial for HR-positive, HER2-negative 
ABC patients.  
Horizon Scanning in Oncology 
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is abemaciclib? 
A0022 Who manufactures abemaciclib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has abemaciclib received marketing authorisation? 
Health problem and current use 
A0002 What is breast cancer? 
A0004 What is the natural course of breast cancer? 
A0006 What are the consequences of breast cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of breast cancer? 
A0003 What are the known risk factors for breast cancer? 
A0024 
How is breast cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is the disease or health condition currently managed according to published 
guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of abemaciclib on mortality? 
D0005 
How does abemaciclib affect symptoms and findings (severity, frequency) of breast 
cancer? 
D0006 How does abemaciclib affect progression (or recurrence) of breast cancer? 
D0011 What is the effect of abemaciclib on patients ̕ body functions? 
D0012 What is the effect of abemaciclib on generic health-related quality of life? 
D0013 What is the effect of abemaciclib on disease-specific quality of life? 
Safety 
C0008 How safe is abemaciclib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying abemaciclib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of abemaciclib? 
A0021 What is the reimbursement status of abemaciclib? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Abemaciclib/Verzenio

/LY2835219 
 
B0001: What is abemaciclib? 
Abemaciclib (LY2835219) is an orally available cyclin-dependent kinase 
(CDK) inhibitor, which specifically inhibits the activities of the cyclin D-
dependent kinases CDK4 and CDK6. During the cell-division cycle abema-
ciclib arrests progression through the G1 phase and thereby promotes tran-
sient cell-cycle withdrawal into a quiescent state (G0) or into a permanent 
proliferation inhibition (senescence). As a result DNA synthesis is supressed 
and cancer cell growth stopped [2-5]. 
According to clinical trials, the recommended dose of abemaciclib is 150 mg 
administered orally twice daily given continuously in combination with 
500 mg of fulvestrant by intramuscular injection on days one and 15 of the 
first cycle (28 days) and on day one of subsequent cycles. 
 
A0022: Who manufactures abemaciclib? 
Eli Lilly and Company 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Abemaciclib in combination with fulvestrant is indicated for treatment of 
hormone-receptor (HR)-positive, human epidermal growth factor 2 
(HER2)-negative advanced breast cancer (ABC) patients, who have pro-
gressed while receiving endocrine therapy (ET). 
 
 
 
 
 
 
orally available, 
selective CDK inhibitor 
150 mg twice daily on a 
continuous schedule 
HR-positive, HER2-
negative ABC patients 
Abemaciclib in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC) 
LBI-HTA | 2017 9 
4 Current regulatory status 
A0020: For which indications has abemaciclib received marketing authorisa-
tion? 
Abemaciclib has been approved by the US Food and Drug Administration 
(FDA) in September 2017 for the following two indications [6]: 
 abemaciclib as monotherapy for patients with HR-positive, HER2-
negative ABC who have received prior ET and chemotherapy for 
metastatic disease 
 abemaciclib in combination with fulvestrant in women with 
HR-positive, HER2-negative ABC who had disease progression fol-
lowing ET 
The submission is based on two clinical trials, the MONARCH 1 and 
MONARCH 2 [6]. 
Currently, abemaciclib has not received marketing authorisation by the Eu-
ropean Medicines Agency (EMA). 
 
 
 
5 Burden of disease 
A0002: What is breast cancer? 
Owing to the molecular pathogenesis of breast cancer, it is designated as a het-
erogeneous malignancy. It arises from the tissues of the breast and most 
commonly originates in the cells that line the ducts due to dysregulation of 
the cell cycle. Breast cancer can be characterised by the pattern of expression 
of the HRs (oestrogen receptor [ER] and progesterone receptor [PR]), the 
HER2 receptor, a clinically relevant third molecular marker, the stage at the 
time of diagnosis and the rate of growth. Prognostically and therapeutically a 
distinction can be made between pre-cancerous conditions like in situ tu-
mours (obligatory pre-cancerous condition: ductal carcinoma in situ [DCIS]; 
optional pre-cancerous condition: lobular carcinoma in situ [LCIS]) and inva-
sive breast cancer [7, 8]. 
 
A0004: What is the natural course of breast cancer? 
Mostly, cancer begins in the cells of the ducts, called ductal carcinoma. Ab-
normal cells are found in the lining of the ducts; however, they have not 
spread into the surrounding tissue and thus state a pre-cancerous condition 
like DCIS (stage 0) [9, 10]. In fact, the development of type A, ductal hyper-
plasia over DCIS, into invasive breast cancer is not veritable. Invasive breast 
cancer, stage I, is restricted to the breast not larger than 2.0 cm (pT1) and 
with only micrometastasis (<2 mm) in the axillary lymph nodes (pNmi). In 
stage II, the tumour is pT0 or pT1 with 1-3 involved axillary lymph nodes 
(pN1) or pT2 with no or 1-3 involved axillary lymph nodes (pN1) or pT3 
since September 2017 
approved by the FDA 
abemaciclib is not 
approved in Europe 
heterogeneous disease 
that arise from the 
tissue of the breast most 
commonly from cells 
lining the ducts 
stages of breast cancer: 
stage 0, stage I, stage II, 
stage III and stage IV 
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with no lymph node involvement. Under stage III, tumours are summarised 
that have different size and lymph node involvement apart from the above 
mentioned without distant metastasis [11]. If the cancer has spread to dis-
tant parts of the body (stage IV) via the lymph system or the blood, it can al-
so be referred to as metastatic breast cancer (MBC) [10].  
Breast cancer can be staged by using the American Joint Committee on Can-
cer (AJCC) tumour node metastasis (TNM) staging system. It involves im-
portant tumour characteristics as well as survival data to support the estima-
tion of outcomes. The TNM staging system classifies tumours on the basis of 
the primary tumour characteristics (T), the presence or absence of regional 
lymph node involvement (N), and the presence or absence of distant metas-
tases (M).  
 
A0006: What are the consequences of breast cancer for the society? 
Due to the aging population and in combination with the fact that higher 
age is strongly related to breast cancer risk, the incidence of cancer will in-
crease over time [12]. Globally, around 30% of the patients with early breast 
cancer develop advanced or MBC [13]. In Austria, breast cancer accounts for 
approximately 28,000 (2.6% of total) life-years lost due to premature deaths 
[14]. Moreover, the incidence of breast cancer is highest for higher socioeco-
nomic groups, whereas survival is lowest in lower socioeconomic groups 
[15]. 
 
A0023: How many people belong to the target population? 
About 30% of all malignant neoplasm cases in Austria are due to breast can-
cer. It is the most common cause of death due to cancer in females. The age 
standardised incidence rate for the European Standard Population (2013) is 
64.3 per 100,000 persons per year. In 2014, 5,454 persons were newly diag-
nosed with breast cancer in Austria, of whom approximately 98% were wom-
en. Moreover, around 86% of female breast cancer patients and 78% of male 
breast cancer patients (all stages are included) are alive at least five years af-
ter diagnosis [16]. The median age at diagnosis of breast cancer is 62 years in 
the US, ranging from 55 to 64 years [17].  
HR-positive disease accounts for approximately 65% and 80% of breast can-
cers in pre- and postmenopausal women, respectively. Accounting for ap-
proximately 70% of breast cancer patients, HR-positive and HER2-negative 
is the most common type of breast cancer. Therefore, about 3,818 of the 
5,454 persons diagnosed with breast cancer in 2014 in Austria were affected 
by HR-positive and HER2-negative disease. Between 5–10% of the patients 
at the time of first presentation have MBC that has spread to other parts of 
the body, e.g., bone, liver, lung and brain and about 30% of people who pre-
sent with localised disease will later develop metastases [15, 18].  
 
A0005: What are the symptoms and the burden of breast cancer? 
A breast mass with irregular borders is the most common symptom of breast 
cancer [19-21]. In addition, symptoms like swelling of the whole or only 
parts of the breast, skin irritation or dimpling (peau d’orange), less often 
breast or nipple pain, nipple retraction, redness, or thickening of the nipple 
or breast skin, nipple discharge or axillary adenopathy can occur [20-22]. In 
AJCC-TNM staging 
system 
increasing incidence of 
cancer 
 
 
highest incidence rate in 
higher socioeconomic 
groups 
incidence rate based on 
the European Standard 
Population: 64.3 per 
100,000 persons/year 
 
 
median age at diagnosis: 
62 
HR-positive, HER2-
negative most common 
breast cancer type; 
~3,818 HR-positive, 
HER2-negative breast 
cancer cases in 2014 in 
Austria 
main symptoms: 
breast mass,  
skin irritation, 
pain 
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advanced stages of breast cancer weight loss and reduced performance can 
be present [22]. Symptoms due to metastases include swelling of the arm be-
cause of lymph node metastases of the axilla, bone pain in skeletal metasta-
ses, cough and dyspnoea in pulmonary and/or pleural metastases, jaundice 
and hepatic failure in advanced liver metastases, or neurological symptoms 
in cerebral metastases [15, 21, 22]. 
 
A0003: What are the known risk factors for breast cancer? 
Established high-risk factors for developing breast cancer are an increasing 
age, female gender and white race. Indeed, obesity as well as mutations in 
genes like BRCA1 and, BRCA2 are associated with an increased risk of 
breast cancer in pre- and postmenopausal women [15, 22-25]. In addition, 
increased exposure to oestrogen like early menarche or late menopause can 
also be a risk factor for the diagnosis of breast cancer [22, 23]. Furthermore, 
reproductive factors may influence the risk including a first pregnancy at 
late age, absence of breastfeeding and nulliparity [23, 24]. Other risk factors 
that may lead to breast cancer are alcohol consumption, smoking, family and 
personal history of breast cancer [24]. 
 
A0024: How is breast cancer currently diagnosed according to published 
guidelines and in practice? 
There are several ways to diagnose breast cancer, such as the clinical breast 
exam (CBE) and imaging like mammography and sonography or magnetic 
resonance imaging (MRI). However, an abnormal mammogram is the most 
common reason for suspecting breast cancer. If breast cancer is suspected in 
the mammogram a sonography, followed by a biopsy (core needle biopsy and 
vacuum-assisted biopsy) have to be performed. An additional breast MRI 
can increase the detection rate of additional lesions, but it does not improve 
the prognosis [22]. In the later stages of the disease, abdominal and thoracic 
diagnostic scans, bone scans can be applied [25]. The positron emission to-
mography (PET) plays a less important role for the diagnosis and staging of 
breast cancer [25]. 
As breast cancer is a heterogeneous disease, it is essential to establish the 
HR and HER2 status [10, 25]. Additionally, the stratification into the differ-
ent disease stages, described in section “A0004: What is the natural course of 
breast cancer?” is crucial to ensure the best therapy.  
 
 
 
6 Current treatment 
A0025: How is breast cancer currently managed according to published 
guidelines and in practice? 
Generally, breast cancer can be treated by surgery, adjuvant irradiation 
and/or systemic therapies [22]. To determine which treatment strategy is the 
most suitable for the patient, several factors are important [20, 22]: 
main risk factors:  
age, gender, race, 
obesity, genes, 
menopausal status 
diagnosis of breast 
cancer via 
mammography, CBE, 
biopsy, blood chemistry 
and x-ray tests 
 
additional use of MRI 
possible to detect 
further lesions 
HR and HER2 status 
 
stratification into 
disease stage 
factors for therapeutic 
decisions 
Horizon Scanning in Oncology 
12 LBI-HTA | 2017 
 stage of cancer (AJCC TNM staging system) 
 grade of disease 
 menopausal status 
 patient health 
 HR and HER2 status 
 proliferation rate estimated by means of a Ki67 test 
The treatment of stage ≤3 breast cancer, where no distant metastases have 
been detected, has a curative intention. The following steps of therapy may 
apply depending on the biology and the stage of the tumour and the perfor-
mance status of the patient [22]: 
 neoadjuvant systemic therapy  
 surgery (mastectomy versus breast conserving therapy [BCT], sen-
tinel lymph node biopsy [SLNB]), axillary node dissection) 
 adjuvant systematic therapy  
 adjuvant radiation therapy 
For patients with locally ABC (stage IIB, IIIA/B) the previously mentioned 
treatment options can be applied as well. In case of metastatic disease (stage 
IV), treatment with a palliative intent (systemic therapy, best supportive 
care, etc.) can be used [22]. 
In particular, treatment options for patients with HR-positive, HER2-
negative advanced or MBC who have not responded to, relapsed or pro-
gressed while receiving ET are [26]:  
 pre- or perimenopause 
o ovarian function suppressing (OFS) + tamoxifen 
o OFS + fulvestrant+ palbociclib, 
o tamoxifen,  
o OFS,  
o OFS + aromatase inhibitors (AI), 
o OFS + fulvestrant, 
o OFS + AI + palbociclib 
 postmenopause 
o letrozol + palbociclib 
o fulvestrant + palbociclib 
o fulvestrant 
o AI 3rd generation 
o exemestan + everolimus 
o tamoxifen 
o eamoxifen + everolimus 
curative treatment 
options for stage ≤3 
breast cancer 
stage IV breast cancer 
treatment options with 
a palliative intent 
treatment options for 
HR-positive, HER2-
negative ABC 
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7 Evidence 
A literature search was conducted on 07 August 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “abemaciclib”, “LY2835219”, “breast cancer”, “breast ne-
oplasms”, “mamma carcinoma”, and “advanced”. The manufacturer was also 
contacted and submitted three references (of which one had already been 
identified by systematic literature search). A manual search identified 34 
additional references (web documents and journal articles). 
Overall, 141 references were identified. Included in this report are the fol-
lowing two studies to assess outcomes on clinical efficacy and safety: 
 One phase III study, assessing abemaciclib in HR-positive, HER2-
negative ABC patients, who had progressed while receiving neoad-
juvant or adjuvant ET [27, 28] 
 One phase II study, assessing the single-agent activity and safety of 
abemaciclib in women with refractory HR-positive, HER2-
negative MBC, who have progressed on or after prior ET and have 
received one or two chemotherapy regimens [29] 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [30]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 of the Appendix. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [31]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [32]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
 
7.1 Clinical efficacy and safety 
 – phase III studies 
The MONARCH 2 trial, a randomised, double-blind, global, placebo-
controlled phase III study, was conducted to assess the addition of abema-
ciclib to fulvestrant for the treatment of HR-positive, HER2-negative ABC 
(inoperable locally advanced or MBC) patients, who have progressed while 
receiving neoadjuvant or adjuvant ET, ≤12 months after adjuvant ET, or 
while receiving ET for ABC [27, 28]. 
systematic literature 
search in 5 databases:  
105 hits 
 
 
manual search: 34 
additional references 
overall: 141 references 
included: 2 studies to 
assess clinical efficacy 
and safety outcomes 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
MONARCH 2: 
randomised, placebo-
controlled, double-blind, 
global, phase III trial 
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Reported are results of the final analysis of the primary endpoint (progres-
sion-free survival [PFS]), which was planned after 378 PFS events (docu-
mented progression or death without documented progression) had oc-
curred. At the time of data cut-off (February 14, 2017) 379 PFS events have 
occurred (n = 222 [49.8%] in the abemaciclib plus fulvestrant arm and n = 
157 [70.4%] in the control arm) in the intention-to-treat (ITT) population. 
170 patients (38.1%) in the abemaciclib arm versus 45 (20.2%) in the place-
bo arm were continuing to receive the study drug at the time of data cut-off, 
whereas 70 (15.9%) in the intervention arm versus seven patients (3.1%) in 
the placebo arm discontinued due to adverse events (AEs). The median 
length of follow-up at the time of data cut-off was 19.5 months; patients in 
the abemaciclib arm received a median of 15 cycles compared with nine cy-
cles in the control arm. 
A total of 669 patients were randomly assigned in a 2:1 ratio to receive 
abemaciclib or placebo (150 mg twice daily) given continuously in combina-
tion with 500 mg of fulvestrant by intramuscular injection on days one and 
15 of the first cycle (28 days) and on day one of subsequent cycles. The strat-
ification of randomisation was based on the metastatic site (visceral, bone 
only, or other) and ET resistance (primary or secondary). Initially the study 
was planned to enrol 450 patients for the ITT population. However, the 
starting dose of the blinded-study drug was changed from 200 mg to 150 mg; 
therefore, the sample size was increased to 630 patients to ensure that at 
least 450 patients receive a dose of 150 mg. Before the mandatory dose-
reduction, 121 (27.4%) patients have received 200 mg of abemaciclib for a 
median of 34 days. 
Enrolled patients were at least 18 years old and had a median age of 59 
(range, 32–91) and 62 (range, 32–87) years in the abemaciclib and placebo 
group, respectively. The study population had an Eastern Cooperative On-
cology Group (ECOG) performance status of 0 or 1. Detailed patient charac-
teristics including inclusion- and exclusion criteria can be found in Table 4. 
The primary outcome of MONARCH 2 was investigator-assessed PFS; key 
secondary outcomes included objective response rate (ORR; e.g., proportion 
of patients with complete response [CR] or partial response [PR]), duration 
of response (DOR; time from CR or PR until progressive disease [PD] or 
death), clinical benefit rate (CBR, CR plus PR plus stable disease ≥6 
months), tolerability and safety. Other secondary endpoints that are not re-
ported in this analysis are overall survival (OS), quality of life (QoL) 
measures and pharmacokinetics. 
 
7.1.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of abemaciclib on mortality? 
OS results were not mature at the time of data cut-off (February 2017); 85 
deaths (19.1%) in the abemaciclib arm and 48 (21.5%) in the placebo arm 
have occurred. 
 
 
 
final analysis of the 
primary endpoint PFS 
 
data cut-off: February 
2017 
 
 
 
 
median of 15 cycles 
(abemaciclib) and nine 
cycles (placebo) 
efficacy and safety of 
abemaciclib and 
fulvestrant vs. placebo 
and fulvestrant 
 
 
 
amendment of the 
starting dose from 200 
to 150 mg 
median age of 59 years 
in the abemaciclib group 
and ECOG performance 
status of 0–1 
primary outcome: PFS 
key secondary 
outcomes: ORR, DOR, 
CBR, safety and 
tolerability 
 
OS and QoL not 
reported in this analysis 
immature OS data at 
the time of data cut-off 
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D0006: How does abemaciclib affect progression (or recurrence) of breast 
cancer? 
PFS, the primary endpoint, showed a statistically significant improvement 
in the ITT population of the abemaciclib arm (p < 0.001). The investigator-
assessed median PFS was 16.4 and 9.3 months in the abemaciclib group and 
the placebo group, respectively. The hazard ratio (HR) for disease progres-
sion of abemaciclib compared to placebo was 0.533 (95% CI 0.449–0.681). 
The blinded central analysis yielded a HR for disease progression of 0.460 
(95% CI 0.363–0.584; p < 0.001). In addition, a sensitivity analysis was con-
ducted that included only those patients, who were enrolled after the change 
of the starting dose, which resulted in a HR for disease progression of 0.588 
(95% CI 0.458–0.754). 
 
D0005: How does abemaciclib affect symptoms and findings (severity, fre-
quency) of breast cancer? 
The ORR in the ITT population was 35.2% (95% CI 30.8–39.6%, n = 157) in 
the abemaciclib arm and 16.1% (95% CI 11.3–21.0%, n = 36) in the placebo 
arm; a CR occurred in 14 patients (3.1%) in the abemaciclib group and in 
one patient (0.4%) in the control group. ORR improvement in the abema-
ciclib arm was statistically significant (p < 0.001).  
In both study groups responses were durable, with 12-month DOR rates of 
67.8% and 66.9% in the abemaciclib arm and the placebo arm, respectively. 
The median DOR had not been reached in the abemaciclib arm. At the time 
of data cut-off, 90 responders (57.3%) continuing to receive treatment. Pa-
tients with measurable disease showed an ORR of 48.1% (95% CI 42.6–
53.6%) in the abemaciclib arm and 21.3% (95% CI 15.1–27.6%) in the con-
trol arm was observed (p > 0.001). 
 
D0011: What is the effect of abemaciclib on patients̕ body functions? 
No evidence was found to answer this research question. 
 
D0012: What is the effect of abemaciclib on generic health-related quality of 
life? 
D0013: What is the effect of abemaciclib on disease-specific quality of life? 
No evidence was found to answer this research questions. Although QoL 
measures are secondary endpoints of the MONARCH 2 study they were not 
reported in the published final analysis of the primary endpoint, PFS. 
 
 
 
 
 
 
positive difference in 
investigator-assessed 
median PFS in the ITT 
population: 7.1 months 
ORR in the ITT 
population 
abemaciclib: 35.2% 
placebo: 16.1% 
12-month DOR rates 
abemaciclib: 67.8% 
placebo: 66.9% 
QoL measures are not 
reported 
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Table 1: Efficacy results of the MONARCH 2 trial 
Descriptive statistics and 
estimate variability 
Treatment group Abemaciclib Placebo 
Number of subject 446 223 
Median PFS (ITT), months 16.4 9.3 
ORR (ITT), % (95% CI) 
CR 
PR 
35.2 (30.8–39.6) 
3.1 (1.5–4.8) 
32.1 (27.7–36.4) 
16.1 (11.3–21.0) 
0.4 (-0.4–1.3) 
15.7 (10.9–20.5) 
OS NA NA 
QoL NA NA 
Effect estimate per com-
parison 
 
Comparison groups 
Abemaciclib+fulvestrant 
versus 
placebo+fulvestrant 
PFS (ITT) HR 0.553 
95% CI 0.449–0.681 
Log-rank test p-value < 0.001 
PFS (blinded central 
analysis) 
HR 0.460 
95% CI 0.363–0.584 
Log-rank test p-value < 0.001 
PFS (starting dose: 
150 mg) 
HR 0.588 
95% CI 0.458–0.754 
Log-rank test p-value NA 
Abbreviations: CI = confidence interval, CR = complete response, HR = hazard ratio, ITT = intention-to-treat population, NA = not 
available, OS = overall survival, PFS = progression-free survival, PR = partial response, QoL = quality of life 
 
7.1.1.1. Safety 
 
C0008: How safe is abemaciclib in relation to the comparator(s)? 
The most frequent AEs in the safety population (abemaciclib, n = 441; pla-
cebo = 223) of any grade were diarrhoea, neutropenia, nausea, fatigue, and 
abdominal pain. Grade ≥3 AEs could be observed in 267 (60.5%) patients in 
the abemaciclib group and in 51 (22.8%) patients in the placebo group. The 
most common grade ≥3 AEs in the abemaciclib group were neutropenia 
(26.5%), diarrhoea (13.4%), leukopenia (8.8%) and anaemia (7.2%). Infec-
tions, regardless of relatedness, occurred more frequently in the abemaciclib 
arm compared to the placebo arm (42.6% vs 24.7%). Serious adverse events 
(SAEs) were more common in the abemaciclib group (22.4%) than in the 
placebo group (10.8%). 
In total 14 deaths (3.2%) occurred in the abemaciclib arm (nine because of 
AEs) and ten (4.5%) in the control arm (two due to AEs). Three deaths 
(0.7%) in the abemaciclib group were related to the study drug, two due to 
sepsis, and one because of viral pneumonia.  
 
C0002: Are the harms related to dosage or frequency of applying 
abemaciclib? 
Discontinuation due to AEs occurred in 70 (15.9%) patients of the abema-
ciclib group and in seven (1.3%) patients of the placebo group. Dose reduc-
tions due to AEs were necessary in 189 (42.9%) patients of the abemaciclib 
grade ≥3 AEs 
abemaciclib: 60.5% 
placebo: 22.8% 
9 deaths due to AEs in 
the abemaciclib group 
dose interruptions 
abemaciclib: 51.9% 
placebo: 11.7% 
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arm and in three (1.3%) patients of the placebo arm. Abemaciclib treatment 
due to AEs was interrupted in 229 (51.9%) patients and treatment interrup-
tions in the placebo arm occurred in 26 (11.7%) patients. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of abemaciclib? 
No evidence was found to answer this research question. 
 
 
Table 2: Most frequent treatment-emergent adverse events 
 
Adverse Event (according  
to CTCAE version 4.0)1 
 
Intervention (n = 441) Control (n = 223) 
 All grades 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
All grades 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any 435 (98.6) 241 (54.6) 26 (5.9) 199 (89.2) 46 (20.6) 5 (2.2) 
Diarrhoea 381 (86.4) 59 (13.4) 0 (0) 55 (24.7) 1 (0.4) 0 (0) 
Neutropenia 203 (46.0) 104 (23.6) 13 (2.9) 9 (4.0) 3 (1.3) 1 (0.4) 
Nausea 199 (45.1) 12 (2.7) - 51 (22.9) 2 (0.9) – 
Fatigue 176 (39.9) 12 (2.7) - 60 (26.9) 1 (0.4) – 
Abdominal pain  156 (35.4) 11 (2.5) - 35 (15.7) 2 (0.9) – 
Anaemia 128 (29.0) 31 (7.0) 1 (0.2) 8 (3.6) 2 (0.9) 0 (0) 
Leukopenia 125 (28.3) 38 (8.6) 1 (0.2) 4 (1.8) 0 (0) 0 (0) 
Decreased appetite 117 (26.5) 5 (1.1) 0 (0) 27 (12.1) 1 (0.4) 0 (0) 
Vomiting 114 (25.9) 4 (0.9) 0 (0) 23 (10.3) 4 (1.8) 0 (0) 
Headache 89 (20.2) 3 (0.7) – 34 (15.2) 1 (0.4) – 
Dysgeusia 79 (17.9) – – 6 (2.7) – – 
Alopecia 69 (15.6) – – 4 (1.8) – – 
Thrombocytopenia 69 (15.6) 9 (2.0) 6 (1.4) 6 (2.7) 0 (0) 1 (0.4) 
Stomatitis 67 (15.2) 2 (0.5) 0 (0) 23 (10.3) 0 (0) 0 (0) 
Constipation 60 (13.6) 3 (0.7) 0 (0) 30 (13.5) 1 (0.4) 0 (0) 
ALT increased 59 (13.4) 17 (3.9) 1 (0.2) 12 (5.4) 4 (1.8) 0 (0) 
Cough 59 (13.4) 0 (0) – 25 (11.2) 0 (0) – 
Pruritus 57 (12.9) 0 (0) – 13 (5.8) 0 (0) – 
Dizziness 55 (12.5) 3 (0.7) – 13 (5.8) 0 (0) – 
AST increased 54 (12.2) 10 (2.3) 0 (0) 15 (6.7) 6 (2.7) 0 (0) 
Blood creatinine level 
increased 52 (11.8) 4 (0.9) 0 (0) 1 (0.4) 0 (0) 0 (0) 
Arthralgia 51 (11.6) 1 (0.2) - 32 (14.3) 1 (0.4) – 
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Edema peripheral 51 (11.6) 0 (0) - 15 (6.7) 0 (0) – 
Rash 49 (11.1) 5 (1.1) 0 (0) 10 (4.5) 0 (0) 0 (0) 
URTI 49 (11.1) 0 (0) 0 (0) 17 (7.6) 2 (0.9) 0 (0) 
Dyspnoea 48 (10.9) 11 (2.5) 1 (0.2) 25 (11.2) 3 (1.3) 0 (0) 
Pyrexia 48 (10.9) 2 (0.5) 1 (0.2) 13 (5.8) 1 (0.4) 0 (0) 
Muscular weakness 47 (10.7) 4 (0.9) – 13 (5.8) 0 (0) – 
Hot flush 46 (10.4) 0 (0) – 22 (9.9) 0 (0) – 
Weight decreased  46 (10.4) 1 (0.2) – 5 (2.2) 1 (0.4) – 
Back pain 42 (9.5) 3 (0.7) – 28 (12.6) 2 (0.9) – 
Abbreviations: ALT = Alanine Aminotransferase, AST = Aspartate Aminotransferase, CTCAE = Common Terminology Criteria 
for Adverse Events, URTI = upper respiratory tract infection, 
1
 = ≥10% of adverse events in either arm, – = grade does not exist 
for this adverse event 
 
 
7.2 Clinical effectiveness and safety –  
further studies 
There is no further study available that has investigated the combination 
treatment of abemaciclib with fulvestrant in HR-positive, HER2-negative 
ABC patients. However, the single-agent activity and safety of abemaciclib 
was evaluated in women with refractory HR-positive, HER2-negative 
MBC, who have progressed on or after prior ET and have received one or 
two chemotherapy regimens [29]. In this single-arm, open-label, phase II 
study (MONARCH 1) 132 women were enrolled to receive 200 mg of 
abemaciclib on a continuous schedule every 12 hours until disease pro-
gression or unacceptable toxicities. The primary outcome was investigator-
assessed ORR. Secondary endpoints included CBR, PFS and OS. 
Enrolled women had received a median of three (range, 1–8) lines of system-
ic therapy in the metastatic setting, 50.8% had ≥3 metastatic sites, and 
90.2% had visceral disease. At the time of final analysis (12-month), the 
primary endpoint of confirmed ORR was 19.7% (95% CI 13.3–27.5); the 
CBR was 42.4%, median PFS was 6.0 months and median OS was 17.7 
months. The most common treatment-emergent AEs of any grade were diar-
rhoea, fatigue, and nausea; the discontinuation rate due to AEs was 7.6%. 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of abemaciclib? 
To date, abemaciclib has not been approved in Europe. Therefore, no price 
estimates are available at this point. 
 
 
MONARCH 1: single-
agent activity and 
safety of abemaciclib in 
HR-positive, HER2-
negative refractory MBC 
confirmed ORR: 19.7% 
median PFS: 6.0 months 
median OS: 17.7 months 
CBR: 42.4% 
no cost estimates 
available yet 
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9 Ongoing research 
In August 2017, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. Three ongoing phase III trials 
investigating abemaciclib in breast cancer were identified: 
 NCT03155997: A randomized, open-label, phase III study of 
abemaciclib combined with standard adjuvant endocrine therapy 
versus standard adjuvant endocrine therapy alone in patients with 
high risk, node positive, early stage, hormone receptor positive, 
human epidermal receptor 2 negative, breast cancer. Estimated 
primary completion date is June 2027. 
 NCT02763566: A randomized, double-blind, placebo-controlled, 
phase III study to compare NSAI (anastrozole or letrozole) plus 
abemaciclib, a CDK4 and CDK6 inhibitor, or plus placebo, and to 
compare fulvestrant plus abemaciclib or plus placebo in postmeno-
pausal women with hormone receptor-positive, HER2-negative lo-
coregionally recurrent or MBC. Estimated primary completion date 
is January 2020. 
 NCT02246621: A randomized, double-blind, placebo-controlled, 
phase III study of nonsteroidal aromatase inhibitors (anastrozole or 
letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in 
postmenopausal women with hormone receptor-positive, HER2-
negative locoregionally recurrent or MBC with no prior systemic 
therapy in this disease setting. Estimated primary completion date 
is July 2021. 
Seven phase II and five phase I studies are currently ongoing in different 
treatment lines in patients with breast cancer, either using abemaciclib 
monotherapy or combination treatment (e.g., NCT03130439, NCT02747004, 
NCT02102490, NCT02675231 and NCT02831530). In addition, abemaciclib 
is currently under investigation in other indications, like dedifferentiated 
liposarcoma, non-small-cell lung cancer, recurrent glioblastoma, melanoma, 
and pancreatic ductal adenocarcinoma. 
 
 
 
10 Discussion 
Currently, abemaciclib is approved for breast cancer since September 2017 
in the US after receiving priority review in July 2017 for the following two 
indications: abemaciclib as monotherapy for patients with HR-positive, 
HER2-negative ABC who have received prior ET and chemotherapy for 
metastatic disease, and abemaciclib in combination with fulvestrant in 
women with HR-positive, HER2-negative ABC who had disease progression 
following ET [6]. However, it has not yet received marketing authorisation 
in Europe. 
3 ongoing phase III 
studies investigating 
abemaciclib in breast 
cancer 
5 ongoing phase I and 7 
ongoing phase II trials in 
different indications and 
treatment lines 
since September 2017 
approved in the US, but 
not in Europe  
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The approval by the FDA for the combination treatment of abemaciclib plus 
fulvestrant is based on the MONARCH 2 trial [27, 28]. The study was con-
ducted to compare abemaciclib plus fulvestrant to placebo plus fulvestrant 
in 669 patients with ABC, who have progressed while receiving ET. At the 
median follow-up of 19.5 months, the primary endpoint PFS showed a sta-
tistically significant increase of 7.1 months (median) in the ITT population 
of the abemaciclib arm compared to the placebo arm (p < 0.001). In addi-
tion, the ORR improvement in the ITT population of the abemaciclib arm 
(+19.1%) was statistically significant (p < 0.001). At the time of data cut-off 
(February 2017), OS results were not mature; 85 deaths (19.1%) in the 
abemaciclib arm and 48 (21.5%) in the placebo arm have occurred (+2.4%). 
QoL outcomes are not reported in the planned final analysis of the primary 
endpoint, PFS. 
Mature OS data and QoL measures are needed as well as further follow-up 
data to ensure a clinical relevant patient benefit over time. In addition, to 
better reflect the most affected patient population, abemaciclib should also 
be investigated in an older patient population (median age of study popula-
tion in the abemaciclib group: 59), as the median age of breast cancer diag-
nosis is 62 years [17]. A gain of 7.1 months in median PFS was not only ob-
served in a slightly younger patient population, but also in a less diseased 
population (ECOG 0–1), and might not be reached in the general patient 
population. Therefore, these patients should be further analysed in future 
trials to identify any advantages or disadvantages, for less fit as well as older 
patients, when treated with abemaciclib. 
In terms of safety, the most frequent AEs of any grade were diarrhoea, neu-
tropenia, nausea, fatigue, and abdominal pain. Grade ≥3 AEs could be ob-
served more commonly in the abemaciclib group (60.5%) than in the place-
bo group (22.8%). The most frequent grade ≥3 AEs in the abemaciclib 
group were neutropenia (26.5%), diarrhoea (13.4%), leukopenia (8.8%) and 
anaemia (7.2%). In addition, discontinuation rates (15.9% vs. 1.3%) as well 
as dose reductions (42.9 vs. 1.3) due to AEs occurred more commonly in the 
abemaciclib group. Moreover, three deaths (0.7%) in the abemaciclib group 
were linked to the study drug, two due to sepsis, and one was because of viral 
pneumonia. 
Gastrointestinal toxicities were the dose-limiting factor in the MONARCH 2 
trial, especially the incidence of diarrhoea was increased with abemaciclib 
(all grades: 86.4% versus 24.7%; grade 3-4: 13.4% versus 0.4%). Thus, the 
administered dose of abemaciclib was reduced from 200 mg to 150 mg after 
121 (27.4%) patients have received the study drug. Therefore, additional in-
vestigations are necessary to better understand the safety profile of abema-
ciclib and to develop management strategies [5].  
Given the non-curative setting of abemaciclib and the statistically signifi-
cant primary endpoint PFS we applied form 2b of the ESMO-MCBS in or-
der to assess whether abemaciclib satisfies the criteria for a “meaningful 
clinical benefit” (score 4 or 5). Both the original as well as the adapted ver-
sion of the MCBS were applied [31, 32]. The application of the 
ESMO-MCBS to the MONARCH 2 study resulted in a grade 3 and 2 in the 
original and the adapted version of the ESMO-MCBS, respectively (Table 3). 
Therefore, abemaciclib does not demonstrate a meaningful clinical benefit 
in either the adapted scale nor in the original framework. Differences in 
scores occur due to the higher implication of toxicities in the adapted 
ESMO-MCBS. 
MONARCH 2 (data cut-
off February 2017): 
statistically significant 
improvement in PFS and 
ORR, but OS was 
immature 
immature OS and 
missing QoL data 
 
 
 
health status and age of 
the study population 
was not representative 
for the actual patient 
population 
grade ≥3 AEs 
more common in the 
abemaciclib group 
 
 
 
three deaths related to 
abemaciclib 
high incidence of 
gastrointestinal 
toxicities 
ESMO-MCBS 
original: 3 
adapted: 2 
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There are methodological limitations of the MONARCH 2 trial that com-
promise internal and external validity. Although patients were randomized 
2:1 to the abemaciclib or placebo arm via interactive, web-based randomiza-
tion scheme, allocation concealment was not maintained, which may lead to 
a selection bias. Besides that, the missing follow-up data of the MONARCH 
2 trial can lead to a systematic overestimation of the treatment effect of 
abemaciclib [33]. However, due to the double-blind study design, the ade-
quate generation of randomisation sequence and an unlikely selective out-
come reporting a low risk of bias could be detected. 
Two other CDK4/6 inhibitors (palbociclib and ribociclib) are already ap-
proved in Europe as well as in the US for the treatment of HR-positive, 
HER2-negative breast cancer [34-37]. Whilst palbociclib and ribociclib have 
comparable toxicity profiles, gastrointestinal toxicities and fatigue are more 
prevalent with abemaciclib [5]. Moreover, in the MONARCH 2 trial prior 
chemotherapy was an exclusion criteria, which was in contrast to the trial 
investigating palbociclib (PALOMA 3) [38]. All these factors have to be con-
sidered in future treatment schemes for HR-positive, HER2-negative breast 
cancer patients to determine the best place of treatment with abemaciclib. In 
addition, though 108 active trials involving these three CDK4/6 inhibitors 
are registered on clinicaltrials.gov none of them perform direct comparisons 
with one another. Consequently, direct comparisons of these agents are nec-
essary in order to identify the best treatment option for HR-positive, HER2-
negative ABC patients. 
At the moment, the only predictive biomarker for CDK4/6 inhibitors clini-
cally used is the HR-positive and HER2-negative breast cancer subtype [39]. 
Therefore, there is a lack of predictive biomarkers, to screen the appropriate 
patient population who would benefit most from these agents [39-43]. The 
selection of sensitive patients may increase patient benefit on the one hand, 
and also improve the cost-effectiveness ratio of these inhibitors on the other 
hand [40]. One candidate could be the retinoblastoma protein (Rb) expres-
sion which is currently evaluated in two ongoing phase I studies 
(NCT01976160, NCT01320592) investigating palbociclib, whereby Rb ex-
pression is one of their inclusion criteria [44]. Moreover, another biomarker 
study is ongoing (NCT03195192), that aims to identify multiomic advanced 
diagnostics to select CDK4/6 inhibitor response predictors [45]. In addition, 
the identification of the mechanisms of de novo and acquired resistance is 
important to prevent the limitation of efficacy of these therapies and to elu-
cidate the most effective CDK4/6 inhibitor approaches [41, 43]. Thus, fur-
ther clinical trials that tackle these important issues are needed.  
There are no price estimates available for abemaciclib, as it has not yet re-
ceived marketing authorisation in Europe. However, the costs of the 
CDK4/6 inhibitor palbociclib of €4,582.55 per 28-day cycle could be taken 
as a proxy variable, since both drugs are indicated for the same target popu-
lation [46]. 
low risk of bias: double-
blind, adequate 
generation of 
randomisation 
sequence, unlikely 
selective outcome 
reporting 
two other approved 
CDK4/6 inhibitors are 
available 
 
 
different safety profiles 
 
 
direct comparisons of 
palbociclib, ribociclib 
and abemaciclib are 
needed 
predictive biomarkers 
required 
 
 
 
 
ongoing biomarker 
studies 
 
 
 
 
 
identification of 
resistance mechanisms 
no price estimates 
available for abemaciclib 
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In conclusion, the treatment with abemaciclib offers a statistically signifi-
cant improvement in PFS of 7.1 months and ORR (+19.1%) with an inferior 
safety profile at high costs. Due to the immature OS data and the missing 
QoL results there is a need of long-term data to avoid a systematic overesti-
mation of the treatment effect of abemaciclib. In future, the identification of 
a robust predictive biomarker to identify the most suitable patients will be 
crucial for the class of CDK4/6 inhibitors. Finally, direct comparisons of 
abemaciclib to palbociclib and ribociclib are essential to investigate which 
treatment option is most beneficial for HR-positive, HER2-negative ABC 
patients. 
 
significant PFS and OS 
improvement, immature 
OS data, missing QoL 
measures 
 
lack of reliable 
biomarkers 
 
comparative studies are 
needed 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [31, 32] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Abemaciclib 
breast 
cancer NC PFS 2b >6 months +7.1 
0.55 
0.45–0.68 
HR ≤0.65 AND Gain ≥3 
months 
3 
+37,7% 
grade 
3–4 AEsA 
x -1 2 
Original 
ESMO-
MCBS 
Abemaciclib 
breast 
cancer NC PFS 2b >6 months +7.1 
0.55 
0.45–0.68 
HR ≤0.65 AND Gain ≥3 
months 
3 x x x 3 
Abbreviations: AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, NC = non-curative, PE = primary endpoint, PFS = pro-
gression-free survival, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of interest, and by 
score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the exact same score resulting from the use 
of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours drugs with a higher degree of uncertainty (broad CI). 
Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes that lead to an up- or downgrading seem to be arbitrary. In addition, they are 
independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjustments separately. 
 
                                                             
A
 Downgrade due to a negative difference of at least 10% in grade ≥3 AEs 
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12 Appendix  
Table 4: Characteristics of trial MONARCH 2 
Title: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had pro-
gressed while receiving endocrine therapy [27, 28] 
Study identifier NCT02107703, EudraCT number 2013-004728-13, MONARCH 2 
Design Global, double-blind, phase III, randomised, placebo-controlled 
Duration Enrolment: August 2014 to December 2015 
 Median length of follow-up: 19.5 months 
 Data cut-off: 2017-02-14 
Hypothesis 
Superiority 
The study was designed to compare the PFS for abemaciclib plus fulvestrant to that for placebo plus 
fulvestrant in patients with ABC. The primary end point, investigator-assessed PFS, was evaluated us-
ing a log-rank test stratified by metastatic site and ET resistance. The final analysis was planned at 
378 PFS events, which would provide approximately 90% power assuming a HR of 0.703 at a one-
sided α of 0.025, which corresponds to a 2.75-month improvement over the median PFS for the con-
trol arm of 6.5 months. 
Funding Eli Lilly and Company 
Treatments groups 
 
Intervention (n = 446) 
Abemaciclib (150 mg twice daily) was administered continu-
ously in combination with 500 mg of fulvestrant by intra-
muscular injection on days 1 and 15 of the first cycle (28 days) 
and on day 1 of subsequent cycles. 
Control (n = 223) 
Placebo (150 mg twice daily) was administered continuously 
in combination with 500 mg of fulvestrant by intramuscular 
injection on days 1 and 15 of the first cycle (28 days) and on 
day 1 of subsequent cycles. 
Endpoints and definitions 
 
Progression-free survival 
(primary outcome) 
PFS Time of random assignment until objective progressive dis-
ease or death for any reason 
Overall survival OS Time from the date pf randomisation to the date of death  
Objective response rate ORR 
Proportion of patients with complete response or partial re-
sponse 
Duration of response DOR Time from complete response or partial response until pro-
gressive disease or death 
Database lock June 2017 
Results and Analysis 
Analysis description Primary Analysis 
Initially the study was planned to enrol 450 patients into the ITT population. However, the starting 
dose of the blinded-study drug was changed from 200 mg to 150 mg; therefore, the sample size was 
increased to 630 patients to ensure that at least 450 patients were enrolled at the 150 mg dose. The 
primary statistical analyses for investigator-assessed PFS were assessed in the ITT population, which 
included all patients independent of their starting dose. Sensitivity analyses were planned that (1) in-
cluded only patients enrolled after the change in starting dose and that (2) determined progression 
on the basis of a blinded, independent central review. 
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Title: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had pro-
gressed while receiving endocrine therapy [27, 28] 
Study identifier NCT02107703, EudraCT number 2013-004728-13, MONARCH 2 
Analysis population   
Inclusion 
 ≥18 year old women 
 Diagnosis of HR+, HER2- breast cancer 
 Locally advanced disease not amenable to curative treatment by surgery or 
metastatic disease 
 Disease that progressed while receiving neoadjuvant or adjuvant ET, ≤12 
months after adjuvant ET, or while receiving ET for ABC. Patients must not 
have received more than one ET or any prior chemotherapy for ABC 
 Postmenopausal status due to either surgical/natural menopause or ovarian 
suppression (initiated at least 28 days prior to Day 1 of Cycle 1) with a gonado-
tropin-releasing hormone (GnRH) agonist such as goserelin 
 Negative serum pregnancy test at baseline (within 14 days prior to randomiza-
tion) and agree to use medically approved precautions to prevent pregnancy 
during the study and for 12 weeks following the last dose of abemaciclib if 
postmenopausal status is due to ovarian suppression with a GnRH agonist 
 Measurable disease or non-measurable bone only disease 
 Performance status ≤1 on the ECOG scale 
 Discontinued previous therapies for cancer for at least 21 days for myelosup-
pressive agents or 14 days for non-myelosuppressive agents prior to receiving 
study drug, and recovered from the acute effects of therapy (until the toxicity 
resolves to either baseline or at least Grade 1) except for residual alopecia or 
peripheral neuropathy 
 
Exclusion 
 Are currently receiving an investigational drug in a clinical trial or participat-
ing in any other type of medical research judged not to be scientifically or 
medically compatible with this study 
 Have visceral crisis, lymphangitis spread, or leptomeningeal carcinomatosis 
visceral crisis is not the mere presence of visceral metastases but implies se-
vere organ dysfunction as assessed by symptoms and signs, laboratory studies, 
and rapid progression of the disease 
 Have clinical evidence or history of CNS metastasis 
 Have received prior treatment with chemotherapy (except for neoadjuvant/ 
adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor 
 Have received treatment with a drug that has not received regulatory approv-
al for any indication within 14 or 21 days prior to randomization of study drug 
for a non-myelosuppressive or myelosuppressive agent, respectively 
 Have received recent (within 28 days prior to randomization) yellow fever 
vaccination 
 Have had major surgery within 14 days prior to randomization of study drug 
to allow for post-operative healing of the surgical wound and site(s) 
 Personal history within the last 12 months of any of the following conditions: 
syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrilla-
tion, or sudden cardiac arrest 
 Inflammatory breast cancer or a history of any other cancer (except non-
melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete 
remission with no therapy for a minimum of 3 years 
 Received an autologous or allogeneic stem-cell transplant 
 Active bacterial or fungal infection, or detectable viral infection 
 Initiated bisphosphonates or approved Receptor activator of nuclear factor 
kappa-B (RANK) ligand targeted agents <7 days prior to randomization 
Characteristics Intervention (n = 446) 
Control 
(n = 223) 
Median age (range), years 59 (32-91) 62 (32-87) 
ET resistance, n (%) 
Primary 
Secondary 
 
111 (24.9) 
326 (73.1) 
 
58 (26.0) 
163 (73.1) 
Most recent ET, n (%) 
Neoadjuvant or adjuvant  
Metastatic 
 
263 (59.0) 
171 (38.3) 
 
133 (59.6) 
85 (38.1) 
Prior AI, n (%) 
Yes 
No 
 
316 (70.9) 
130 (29.1) 
 
149 (66.8) 
74 (33.2) 
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Title: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had pro-
gressed while receiving endocrine therapy [27, 28] 
Study identifier NCT02107703, EudraCT number 2013-004728-13, MONARCH 2 
PgR status, n (%) 
Positive 
Negative 
 
339 (76.0) 
96 (21.5) 
 
171 (76.7) 
44 (19.7) 
Metastatic site, n (%) 
Visceral 
Bone only 
Other 
 
245 (54.9) 
123 (27.6) 
75 (16.8) 
 
128 (57.4) 
57 (25.6) 
38 (17.0) 
Measurable disease, n (%) 
Yes 
No 
 
318 (71.3) 
128 (28.7) 
 
164 (73.5) 
59 (26.5) 
Race, n (%) 
Asian 
Caucasian 
Other 
 
149 (33.4) 
237 (53.1) 
29 (6.5) 
 
65 (29.1) 
136 (61.0) 
13 (5.8) 
ECOG performance status, n (%) 
0 
1 
 
264 (59.2) 
176 (39.5) 
 
136 (61.0) 
87 (39.0) 
Prior chemotherapy for neoadjuvant or adju-
vant treatment, n (%) 
Yes 
No 
 
 
267 (59.9) 
179 (40.1) 
 
 
134 (60.1) 
89 (39.9) 
Menopausal status, n (%) 
Pre- or perimenopause 
Postmenopause 
 
72 (16.1) 
371 (83.2) 
 
42 (18.8) 
180 (80.7) 
Abbreviations: ABC = advanced breast cancer, AI = aromatase inhibitor, CNS = central nervous system, DOR = duration of response, ECOG = 
Eastern Cooperative Oncology Group, ET = endocrine therapy, GnRH = Gonadotropin releasing hormone, HR = hazard ratio, ITT = intention-to-
treat, ORR = overall response rate, OS = overall survival, PFS = progression-free survival, PgR = progesterone receptor 
 
 
 
Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [30] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: interactive, web-based randomization 
scheme yes 
Adequate allocation concealment: no information available unclear 
Blinding: 
double-blind 
Patient yes 
Treating physician yes 
Selective outcome reporting unlikely: confidence intervals of the median PFS values for 
both treatment arms are not available as well as median PFS values of the blinded central 
analysis and the sensitivity analysis 
no 
No other aspects which increase the risk of bias: industry funded the study, provided study 
drugs, and was involved in conception and study design, provision of study material or pa-
tients, collection and assembly of data, data analysis and interpretation, and writing of the 
manuscript, missing follow-up data 
no 
Risk of bias – study level low 
Abbreviations: PFS = progression-free survival 
 
 
